Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.

Abstract: Combinations comprising antibody drug conjugates (ADCs) and immunotherapeutic agents (IMTs) are provided. Methods of using such combinations in therapy, e.g. for treatment of cancer, are also provided.

Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.

Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.

Abstract: The present invention is concerned with antibody-drug conjugates (ADCs) for use in cancer immunotherapy. The invention provides an ADC in combination with an immunotherapy (IMT) agent for use in cancer treatment. For example: The invention provides an ADC for use in cancer immunotherapy, wherein the use comprises administering to a patient the ADC in combination with an IMT agent. The invention also provides an IMT agent for use in cancer immunotherapy, wherein the use comprises administering to a patient the IMT agent in combination with an ADC. The invention provides an ADC and an IMT agent for use in cancer immunotherapy, wherein the use comprises administering to a patient the ADC in combination with the IMT agent. The invention provides an ADC for use in cancer immunotherapy, wherein the use comprises simultaneously, separately or sequentially administering to a patient the ADC in combination with an IMT agent.

Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof, used in methods related to cancer stem cells, e.g., binding to a cancer stem cell. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates. In certain aspects, the ASCT2-binding molecules bind specifically to cancer stem cells expressing ASCT2.

Abstract: The invention features doxorubicin or Doxil in combination with a checkpoint inhibitor (e.g., an anti-CTLA-4 antibody, anti-PD-1 antibody, an anti-PD-L1 antibody, GITR ligand, or OX40 fusion protein (FP) and methods of using the combination to enhance anti-tumor activity in a subject.

Abstract: This disclosure provides ASCT2-binding molecules, e.g., anti-ASCT2 antibodies, and antigen-binding fragments thereof. In certain aspects, the ASCT2-binding molecules are conjugated to cytotoxic drugs, e.g., ASCT2 antibody-drug conjugates (ADCs). In certain aspects, the anti-ASCT2 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects, the ASCT2-binding molecules bind specifically to cells expressing ASCT2, and in some instances, are internalized into the cells. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders characterized by ASCT2 overexpression, e.g., certain types of cancer. In a particular embodiment, the disclosure provides methods for treating cancer using ASCT2 ADCs.

Abstract: A solid-state floppy disk drive is disclosed. In one embodiment, a solid-state floppy disk drive may include a non-volatile memory and a connector for coupling the solid-state floppy disk drive to a computer system. The non-volatile memory may store instructions and data which may allow the solid-state floppy disk drive to emulate a mechanical floppy disk drive having a bootable floppy disk inserted into it. The computer system may be booted using the solid-state floppy disk drive.

Abstract: System and method for providing information to a user about an electronic device. One or more diagnostic tests may be performed on the electronic device which indicate whether the electronic device is able to properly operate. Correspondingly, one or more problems may be identified with regard to the operation of the electronic device based on the one or more diagnostic tests. The problems may include configuration problems, e.g., where the user has improperly set up the electronic device and/or malfunctions, e.g., where a component has failed. Additionally, one or more speech phrases may be audibly presented to the user which indicate the problem(s). The speech phrase(s) may also indicate to the user how to solve the problem and/or what resources may be used to solve the problem. The method may also present a tutorial to the user which guides the user in configuring at least a portion of the electronic device.

Abstract: The present invention relates to a novel human patched-like gene (PTCH2), which for the first time has been cloned and sequenced. Several alternatively spliced mRNA forms of PTCH2 have been identified, including transcripts lacking segments thought to be involved in sonic hedgehog (SHH) binding and mRNAs with differentially defined 3? terminal exons. Further, the invention also relates to the protein encoded by the present PTCH2 as well as to functional analogues and variants thereof.

Abstract: The present invention relates to a novel human patched-like gene (PTCH2), which for the first time has been cloned and sequenced. Several alternatively spliced mRNA forms of PTCH2 have been identified, including transcripts lacking segments thought to be involved in sonic hedgehog (SHH) binding and mRNAs with differentially defined 3′ terminal exons. Further, the invention also relates to the protein encoded by the present PTCH2 as well as to functional analogues and variants thereof.

Abstract: A solid-state floppy disk drive is disclosed. In one embodiment, a solid-state floppy disk drive may include a non-volatile memory and a connector four coupling the solid-state floppy disk drive to a computer system. The non-volatile memory may store instructions and data which may allow the solid-state floppy disk drive to emulate a mechanical floppy disk drive having a bootable floppy disk inserted into it. The computer system may be booted using the solid-state floppy disk drive.

Abstract: A polypeptide of the amino acid sequence of SEQ ID NO: 2, and a composition including the polypeptide of SEQ ID NO: 2 bound to cyclin-dependent kinase 2 (Cdk2).

Abstract: Apparatus and methods for creating and applying flexible, user defined rules for placement of graphical objects in a computer aided drafting (CAD) application. The rules for precise placement and overplotting of graphical objects may be defined by a user with significant flexibility. The user defined rules are applied by the placement subsystem of the present invention to automate the proper placement of graphical objects according to the specific rules of the particular user. CAD systems are enhanced by their integration with the automated placement subsystem of the present invention.